Hatchpak IB H120 Neo Effervescent Tablet for Nebuliser Suspension for Chickens

Summary of Product characteristics

                                Revised: June 2021
AN: 00916/2020
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
HATCHPAK IB H120 NEO effervescent tablet for nebuliser suspension for
chickens
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
EACH DOSE CONTAINS:
ACTIVE SUBSTANCE:
Live Infectious Bronchitis virus, H120 strain
.............................3.7 to 4.7 log
10
EID
50
(*)
(*) EID
50
: 50 per cent egg infective dose
EXCIPIENT(S):
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Effervescent tablet for nebuliser suspension.
Orange mottled, round tablet.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
One-day-old chickens.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In one-day-old chickens: active immunisation against Infectious
Bronchitis in order to
reduce infection with Massachusetts serotype of Infectious Bronchitis
virus.
Onset of immunity: 21 days.
Duration of immunity: 6 weeks after a single administration.
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Vaccinate healthy birds only.
Revised: June 2021
AN: 00916/2020
Page 2 of 5
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Vaccine viruses can spread to unvaccinated birds. Infection of
unvaccinated chickens
with the vaccine virus from vaccinated birds does not cause any signs
of disease.
Reversion to virulence trials carried out in the laboratory have shown
that the vaccine
viruses do not acquire any pathogenic characteristics after at least 5
passages in
chickens.
Special precautions to be taken by the person administering the
veterinary medicinal
product to animals
Wash and disinfect hands and equipment after vaccinating.
For more information, contact the manufacturer.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Bronchial rales, not associated with respiratory distress or any
general sign, are very
common between 5 and 14 days after vaccination.
The frequency of adverse reactions is defined using the following
convention:
- very common (more than 1 in 10 ani
                                
                                Read the complete document